Tag Archives: SGLT2 Inhibitor

ESC 2020 | Nuevo inhibidor SGLT2 con impacto en la mortalidad por insuficiencia cardíaca

ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality

ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality

Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in patients with heart failure, even in those without diabetes. Adding empagliflozin to optimal medical therapy lowers the risk of cardiovascular events in patients with heart failure and reduced ejection fraction. Such events include heart failure hospitalization, worsening kidney

Top